QLGN - Qualigen Therapeutics, Inc.

3.51
0.035   0.997%

Share volume: 21,535
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$3.48
0.03
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 0%
Dept financing 50%
Liquidity 41%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.55%
1 Month
-3.57%
3 Months
5.09%
6 Months
3,242.86%
1 Year
1,089.83%
2 Year
276.61%
Key data
Stock price
$3.51
P/E Ratio 
0.00
DAY RANGE
$3.12 - $3.60
EPS 
-$3.24
52 WEEK RANGE
$0.08 - $5.14
52 WEEK CHANGE
$1,070.78
MARKET CAP 
2.280 M
YIELD 
N/A
SHARES OUTSTANDING 
12.156 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
3.61
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$109,494
AVERAGE 30 VOLUME 
$109,414
Company detail
CEO: Michael S. Poirier
Region: US
Website: qualigeninc.com
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Qualigen Therapeutics, Inc. develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers.

Recent news
loading